Last reviewed · How we verify
Iscar
Iscar is a Small molecule drug developed by National Center for Complementary and Integrative Health (NCCIH). It is currently in Phase 2 development.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Iscar |
|---|---|
| Sponsor | National Center for Complementary and Integrative Health (NCCIH) |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma (PHASE2)
- Therapeutic Instillation of Mistletoe (PHASE3)
- Viscum Album for TNBC on Adjuvant Pembrolizumab (PHASE4)
- Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors (PHASE4)
- Mistletoe Therapy in Primary and Recurrent Inoperable Pancreatic Cancer (PHASE3)
- Trial of Mistletoe Extract in Patients With Advanced Solid Tumors (PHASE1)
- Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma
- A Prospective Dose Finding Study of Iscador Infusion (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iscar CI brief — competitive landscape report
- Iscar updates RSS · CI watch RSS
- National Center for Complementary and Integrative Health (NCCIH) portfolio CI
Frequently asked questions about Iscar
What is Iscar?
Who makes Iscar?
What development phase is Iscar in?
Related
- Manufacturer: National Center for Complementary and Integrative Health (NCCIH) — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing